Sam Chun Dang Pharm Valuation

Is A000250 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A000250 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A000250's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A000250's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A000250?

Key metric: As A000250 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A000250. This is calculated by dividing A000250's market cap by their current revenue.
What is A000250's PS Ratio?
PS Ratio	11.9x
Sales	₩204.28b
Market Cap	₩2.60t

A000250 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	12.7x
Enterprise Value/EBITDA	154.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A000250's PS Ratio compare to its peers?

The above table shows the PS ratio for A000250 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.3x
A128940 Hanmi Pharm	2.3x	8.2%	₩3.6t
A009420 Hanall Biopharma	13.2x	13.4%	₩1.8t
A069620 Daewoong Pharmaceutical	1x	4.7%	₩1.5t
A185750 Chong Kun Dang Pharmaceutical	0.7x	3.3%	₩1.2t
A000250 Sam Chun Dang Pharm	11.9x	n/a	₩2.6t

Price-To-Sales vs Peers: A000250 is expensive based on its Price-To-Sales Ratio (11.9x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does A000250's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$159.05m
A096760 JW Holdings	0.2x	n/a	US$151.76m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$93.30m
A000230 Ildong Holdings	0.1x	n/a	US$57.08m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A000250 is expensive based on its Price-To-Sales Ratio (11.9x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A000250's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A000250 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	11.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A000250's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩521.4b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩20,550.00

1.5%

-31.5%

Medy-Tox

₩869.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,900.00

0.5%

-41.1%

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%